Viral sepsis is rare, and its real incidence is not known. SARS-CoV-2 infection causes the release of a significant amount of pro-inflammatory cytokines that aggravates interstitial pneumonia and evolves in viral sepsis with prominent hypercoagulability. We believe it is useful and advisable to establish early immunomodulator therapy and the prophylaxis anticoagulant therapy should be rethought.
Thromboinflammatory response in SARS-CoV-2 sepsis / Maiese, A.; Passaro, G.; de Matteis, A.; Fazio, Valentina; LA RUSSA, Raffaele; Paolo, M. D.. - In: THE MEDICO-LEGAL JOURNAL. - ISSN 0025-8172. - (2020), pp. 1-3. [10.1177/0025817220926915]
Thromboinflammatory response in SARS-CoV-2 sepsis
Maiese A.;de Matteis A.;valentina Fazio.;la russa Raffaele;
2020
Abstract
Viral sepsis is rare, and its real incidence is not known. SARS-CoV-2 infection causes the release of a significant amount of pro-inflammatory cytokines that aggravates interstitial pneumonia and evolves in viral sepsis with prominent hypercoagulability. We believe it is useful and advisable to establish early immunomodulator therapy and the prophylaxis anticoagulant therapy should be rethought.| File | Dimensione | Formato | |
|---|---|---|---|
|
Maiese_Thromboinflammatory_2020.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
259.31 kB
Formato
Adobe PDF
|
259.31 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
